| Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes A Raza, P Meyer, D Dutt, F Zorat, L Lisak, F Nascimben, M du Randt, ... Blood, The Journal of the American Society of Hematology 98 (4), 958-965, 2001 | 455 | 2001 |
| Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes V Shetty, S Mundle, S Alvi, M Showel, LT Broady-Robinson, S Dar, ... Leukemia research 20 (11-12), 891-900, 1996 | 244 | 1996 |
| The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes F Zorat, V Shetty, D Dutt, L Lisak, F Nascimben, K Allampallam, S Dar, ... British journal of haematology 115 (4), 881-894, 2001 | 207 | 2001 |
| Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. A Raza, S Mundle, V Shetty, S Alvi, H Chopra, L Span, A Parcharidou, ... International journal of hematology 63 (4), 265-278, 1996 | 200 | 1996 |
| Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy … A Raza, S Buonamici, L Lisak, S Tahir, D Li, M Imran, NI Chaudary, ... Leukemia research 28 (8), 791-803, 2004 | 117 | 2004 |
| Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic … SD Mundle, P Venugopal, JD Cartlidge, DV Pandav, L Broady-Robinson, ... | 113 | 1996 |
| Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia P Venugopal, S Sivaraman, XK Huang, J Nayini, SA Gregory, HD Preisler Leukemia research 24 (5), 411-415, 2000 | 97 | 2000 |
| Correlation of tumor necrosis factor α (TNFα) with high caspase 3-like activity in myelodysplastic syndromes SD Mundle, S Reza, A Ali, BY Mativi, V Shetty, P Venugopal, SA Gregory, ... Cancer Letters 140 (1-2), 201-207, 1999 | 92 | 1999 |
| Evidence for involvement of tumor necrosis factor‐α in apoptotic death of bone marrow cells in myelodysplastic syndromes SD Mundle, A Ali, JD Cartlidge, S Reza, S Alvi, MM Showel, BY Mativi, ... American journal of hematology 60 (1), 36-47, 1999 | 87 | 1999 |
| A paradigm shift in myelodysplastic syndromes A Raza, S Mundle, V Shetty, S Alvi, H Chopra, L Span, A Parcharidou, ... | 84 | 1996 |
| Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study H Kantarjian, S Faderl, G Garcia-Manero, S Luger, P Venugopal, ... The Lancet Oncology 13 (11), 1096-1104, 2012 | 64 | 2012 |
| Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. SD Mundle, BY Mativi, K Bagai, G Feldman, P Cheema, U Gautam, ... International journal of hematology 70 (2), 83-90, 1999 | 54 | 1999 |
| P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients HD Preisler, B Li, H Chen, L Fisher, J Nayini, A Raza, S Creech, ... Leukemia 15 (10), 1589-1595, 2001 | 53 | 2001 |
| Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia S Sivaraman, P Venugopal, R Ranganathan, CG Deshpande, X Huang, ... Cytokines, cellular & molecular therapy 6 (2), 81-87, 2000 | 53 | 2000 |
| Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine. A Raza, S Alvi, L Broady-Robinson, M Showel, J Cartlidge, SD Mundle, ... Experimental hematology 25 (6), 530-535, 1997 | 53 | 1997 |
| SCF, IL-1β, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients M Tao, B Li, J Nayini, CB Andrews, RW Huang, E Devemy, S Song, ... Cytokine 12 (6), 699-707, 2000 | 52 | 2000 |
| The relative extent and propensity of CD34+ vs. CD34-cells to undergo apoptosis in myelodysplastic marrows. S Mundle, P Venugopal, V Shetty, A Ali, H Chopra, H Handa, S Rose, ... International journal of hematology 69 (3), 152-159, 1999 | 42 | 1999 |
| The evolving role of alemtuzumab in management of patients with CLL S Faderl, S Coutre, JC Byrd, C Dearden, A Denes, MJS Dyer, SA Gregory, ... Leukemia 19 (12), 2147-2152, 2005 | 41 | 2005 |
| The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia … R Rao, JM Shammo, SH Enschede, C Porter, SS Adler, P Venugopal, ... Clinical lymphoma 6 (1), 26-30, 2005 | 35 | 2005 |
| Suppression of Telomerase Activity and Cytokine Messenger RNA Levels in Acute Myelogenous Leukemia Cells in Vivo in Patients by Amifostine and Interleukin 4 HD Preisler, B Li, J Yang, RW Huang, E Devemy, P Venugopal, M Tao, ... Clinical Cancer Research 6 (3), 807-812, 2000 | 35 | 2000 |
Henry C Fung MD FRCPE FACPChair, Department of BMT & Cellular Therapy, Fox Chase Cancer CenterVerified email at tuhs.temple.edu
